Tardive dyskinesia treated with pimozide. 1975

L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch

We have investigated the action of pimozide in tardive dyskinesia induced by prolonged administration of phenothiazines. Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18.8 mg/day) for 6 weeks. There was no deterioration in the therapeutic action of pimozide over this time. Parkinsonism and sedation were the main adverse effects. They were corrected by reduction of the dose of pimozide, but often recurred so that further adjustments of dosage were necessary. Our findings support the view that tardive dyskinesia is produced by a disturbance in the balance of central transmitters such that dopaminergic transmission is increased.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009069 Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D010546 Perphenazine An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE. Chlorpiprazine,Perfenazine,Trilafon
D010640 Phenothiazines Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive.
D010868 Pimozide A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) Antalon,Orap,Orap forte,R-6238,R6238
D011346 Prochlorperazine A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Compazine,Prochlorperazine Edisylate,Prochlorperazine Edisylate Salt,Prochlorperazine Maleate,Edisylate Salt, Prochlorperazine,Edisylate, Prochlorperazine,Maleate, Prochlorperazine,Salt, Prochlorperazine Edisylate
D011395 Promazine A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine Hydrochloride,Protactyl,Sinophenin,Sparine,Hydrochloride, Promazine
D011398 Promethazine A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. Proazamine,Atosil,Diphergan,Diprazin,Isopromethazine,Phenargan,Phenergan,Phensedyl,Pipolfen,Pipolphen,Promet,Prometazin,Promethazine Hydrochloride,Prothazin,Pyrethia,Remsed,Rumergan,Hydrochloride, Promethazine

Related Publications

L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
January 1977, Proceedings of the Royal Society of Medicine,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
January 1980, The Kurume medical journal,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
October 1977, Canadian Medical Association journal,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
September 1990, Journal of the National Medical Association,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
July 1977, Canadian Medical Association journal,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
March 2024, JAAD case reports,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
November 2004, Journal of psychiatry & neuroscience : JPN,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
January 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
December 1979, The British journal of psychiatry : the journal of mental science,
L E Claveria, and P F Teychenne, and D B Calne, and L Haskayne, and A Petrie, and C A Pallis, and I C Lodge-Patch
January 2020, Tijdschrift voor psychiatrie,
Copied contents to your clipboard!